Rituximab, Lenalidomide, and Orelabrutinib Combination Regimen in the Treatment of marginal zone cell lymphoma: a Prospective, Single-Arm, Phase II Clinical Study (ChiCTR) - Oct 16, 2026 - P2 | N=46 | Recruiting | Sponsor: The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital, College of Medicine, Zhejiang University | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Oncology • CD20
|